Wall Street’s major averages ended mostly lower on Friday, as market participants have been keeping an eye on the highly anticipated meeting between Donald Trump and Vladimir Putin. However, the S&P ...

Consumers who pay privately for the Mounjaro weight loss drug could have to shell out thousands more if they want to continue with the treatment, after manufacturer Eli Lilly announced an increase to ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

Eli Lilly recently spoke out against proposed tariffs on pharmaceuticals, warning they could increase drug costs and restrict patient access. The drugmaker said it has invested more than $50 billion ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...